Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancer

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancer

Background: Current standard of care for patients with HR+/HER2− early breast cancer (EBC) includes adjuvant endocrine therapy with an aromatase inhibitor (AI) or tamoxifen (TAM). We present a trial-level meta-analysis on efficacy of AI vs TAM in patients with HR+/HER2− EBC. Methods: A systematic li...

Full description

Saved in:
Bibliographic Details
Main Authors: Wolfgang Janni, Michael Untch, Nadia Harbeck, Joseph Gligorov, William Jacot, Stephen Chia, Jean-François Boileau, Subhajit Gupta, Namita Mishra, Murat Akdere, Andriy Danyliv, Giuseppe Curigliano
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Breast
Subjects:
Meta-analysis
HR+/HER2− early breast cancer
Adjuvant endocrine therapy
Tamoxifen
Aromatase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625000487
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S0960977625000487

Similar Items